In‑Vitro Data That Moves Fast, Like Your Skin
CYTOGEN Masque accelerated keratinocyte gap closure in a standard scratch assay, reaching near-complete closure as early as 32 hours at the lowest tested dose (0.3 mg/mL).
In-vitro study in HaCaT keratinocytes.
~88%
Wound closure at 32h with 0.3 mg/mL
*Mean near-complete closure observed at 32h for the lowest concentration.
≈2×–3× faster
vs. control to reach high closure levels
Control reached ~79% closure at 72h.
HB‑EGF Benchmarked
Assay validated with a known positive control
HB‑EGF (100 ng/mL) approached 100% by 48–56h.
Key Findings
- Lowest dose (0.3mg/mL) reached near-complete closure by 32 hours.
- Higher doses showed progressively smaller effects - an inverse trend often seen in vitro and worth dose-optimization.
- Controls closed ~79% by 72 hours, confirming baseline migration speed.
Data form HaCaT keratinocyte scratch assay; 7 timepoints over 72h.
How We Tested
Model:
HaCaT keratinocyte monolayer scratch (gap-closure) assay; images analyzed at 0, 8, 24, 32, 48, 56, 72 h.
Test Item:
CYTOGEN Masque extract at 0.3, 0.75, 1.5 mg/mL.
Controls:
Vehicle control; HB-EGF (100 ng/mL) as positive control.
Medium:
FCS-free DMEM, 3-day treatment; closure quantified as % of initial wound area.
Why it matters
This assay measures how quickly skin cells migrate to close a wound. It's a standard model for evaluating repair mechanisms and limitations in controlled lab conditions.
Why 0.3 mg/mL is shown
- Scientific credibility: optimal window; lower can work best; efficacy at low exposure; non-linear response.
- Real-world bridge: naming the tested level links lab data to realistic use.
In-vitro data. Not a drug. Not intended to diagnose, treat, cure, or prevent any disease.
Glossary
Experience CYTOGEN Masque
CYTOGEN Masque moves beyond superficial radiance. It’s a barrier reset rooted in regenerative science — helping skin recover, renew, and build lasting resilience.
